US 12,070,449 B2
Methods of treating TTR amyloidosis using AG10
Uma Sinha, San Francisco, CA (US); and Satish Rao, San Francisco, CA (US)
Assigned to EIDOS THERAPEUTICS, INC., Palo Alto, CA (US)
Filed by EIDOS THERAPEUTICS, INC., San Francisco, CA (US)
Filed on May 27, 2021, as Appl. No. 17/332,359.
Application 17/332,359 is a continuation of application No. 16/361,587, filed on Mar. 22, 2019, granted, now 11,058,668.
Claims priority of provisional application 62/810,651, filed on Feb. 26, 2019.
Claims priority of provisional application 62/758,235, filed on Nov. 9, 2018.
Claims priority of provisional application 62/731,629, filed on Sep. 14, 2018.
Claims priority of provisional application 62/765,096, filed on Aug. 17, 2018.
Claims priority of provisional application 62/647,411, filed on Mar. 23, 2018.
Prior Publication US 2022/0016081 A1, Jan. 20, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/415 (2006.01)
CPC A61K 31/415 (2013.01) 20 Claims
 
1. A method of treating transthyretin amyloidosis (ATTR) cardiomyopathy in a subject in need thereof, the method comprising orally administering to a subject in need thereof a total daily dosage of about 1,600 milligrams (mg) of Compound 1 in HCl salt form or an equivalent amount of Compound 1 in freebase or in a different salt form, wherein Compound 1 has the Formula:

OG Complex Work Unit Chemistry
wherein Compound 1 in HCl salt form or an equivalent amount of Compound 1 in freebase or in a different salt form is administered twice daily.